Lymphoma & CLL Subtypes

A retrospective study of the clinical and pathological features of peripheral T-cell lymphomas in a Spanish population

Subclassifying T-cell lymphomas (TCLs) is difficult due to the heterogeneity and...

FDA grants orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma

On July 23, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to cobomarsen...

IRC recommends to focus on one dosage arm to complete the PARADIGME phase IIb trial

On August 6, 2020, after a planned interim analysis of the PARADIGME phase IIb trial, the Independent Review...

Phase II study of tisagenlecleucel in patients with R/R FL meets its primary endpoint

On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating...

FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL

On July 31, 2020, the U.S. Food and Drug Administration (FDA) approved tafasitamab in...

Results from phase I ALEXANDER study investigating the first CAR T-cell therapy, AUTO3, plus pembrolizumab to target both CD19 and CD22 in the treatment of R/R DLBCL

Available CD19 chimeric antigen...

Acalabrutinib receives CHMP positive opinion for the treatment of patients with chronic lymphocytic leukemia

On 23 July, 2020, acalabrutinib received a positive opinion by the Committee for Medicinal...

An update in CLL from EHA 2020

Podcast with Susan O'Brien, University of California Irvine, on the latest updates on CLL from EHA 2020.